Defining Healthy Weight Loss and Target Weight in the Era of Highly Effective Treatment of Patients With Obesity
Journal of Cachexia, Sarcopenia and Muscle · 2026-08 · 17 (4)
DOI: 10.1002/jcsm.70334 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 15.07.2026. Verfasst von Anja Bosy-Westphal und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Nutrition, Institute of Human Nutrition and Food Science, Kiel University, Kiel, Germany. Hauptthemen laut MEDLINE: Weight Loss, Obesity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Highly effective anti‐obesity medications (AOMs) induce substantial weight loss and have renewed debate on appropriate treatment targets. Weight loss comprises reductions in fat mass (FM) and fat‐free mass (FFM), with skeletal muscle (SM) as the major component of FFM. Clinical trials report that 20%–40% of total weight loss is attributable to FFM, raising concerns about excessive SM loss and sarcopenia risk.
Methods
This narrative review integrates physiological principles and quantitative data from clinical trials to derive a rationale for redefining healthy weight loss targets based on body composition. Determinants of energy partitioning (baseline adiposity, age, diet and physical activity) are combined with predictive and reference‐based approaches. Skeletal muscle index (SMI) was estimated from FFM, body weight, sex and age ( R 2 = 0.87, SEE = 0.635 kg/m 2 ) and evaluated using SMI standard deviation scores (SDS).
Results
SM accounts for 92%–97% of FFM loss during weight reduction. In incretin‐based trials, FM decreased by −18.7% to −33.9% and FFM by −6.8% to −10.9%, corresponding to 33%–38% of total weight loss. Model‐based estimates predict lower FFM reductions (~6.8%–6.9%), indicating that observed FFM losses exceed physiological expectations under conditions of large energy deficits. Across studies, diet‐ or AOM‐induced weight loss without structured exercise is associated with higher proportions of FFM loss than expected, whereas interventions including exercise show more favourable partitioning. An SMI‐SDS threshold of −0.67 (25th percentile) identifies clinically relevant SM depletion.
Conclusions
Disproportionate SM loss is common with considerable weight reduction and may exceed physiologically expected levels. An SMI‐based framework enables definition of individualized, safe treatment targets and may help prevent sarcopenia during obesity treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Human Nutrition, Institute of Human Nutrition and Food Science, Kiel University, Kiel, Germany.
- German Institute of Nutritional Science, University of Potsdam, Department of Nutrition and Gerontology, German Institute of Human Nutrition Potsdam-Rehbrücke, Nuthetal, Germany.
- Department of Geriatrics and Medical Gerontology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
ORCID-Profile: Anja Bosy-Westphal, Janna Enderle
Zitieren
APA
Bosy-Westphal, A., Enderle, J., Norman, K., & Müller, M. J. (2026). Defining Healthy Weight Loss and Target Weight in the Era of Highly Effective Treatment of Patients With Obesity. Journal of Cachexia, Sarcopenia and Muscle, 17(4). https://doi.org/10.1002/jcsm.70334
Vancouver
Bosy-Westphal A, Enderle J, Norman K, Müller MJ. Defining Healthy Weight Loss and Target Weight in the Era of Highly Effective Treatment of Patients With Obesity. Journal of Cachexia, Sarcopenia and Muscle. 2026;17(4). doi:10.1002/jcsm.70334
BibTeX
@article{BosyWestphal2026,
author = {Bosy-Westphal, Anja and Enderle, Janna and Norman, Kristina and Müller, Manfred J},
title = {Defining Healthy Weight Loss and Target Weight in the Era of Highly Effective Treatment of Patients With Obesity},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2026},
volume = {17},
number = {4},
doi = {10.1002/jcsm.70334}
}
EUVIMED